Johnson & Johnson has received marketing authorization for BALVERSA® (erdafitinib) as a treatment for adults with unresectable or metastatic urothelial carcinoma (UC) in the UK. This targeted therapy is for patients with fibroblast growth factor receptor 3 (FGFR3) genetic alterations who have not responded to other treatments. The authorization is based on the positive results from the Phase 3 THOR study, showing erdafitinib significantly improved overall and progression-free survival compared to chemotherapy. The most common adverse reactions include hyperphosphatasemia, diarrhea, and stomatitis. Johnson & Johnson is committed to delivering innovative therapies for cancer patients and is working towards making erdafitinib available through the NHS.
Source link
Novel bladder cancer treatment gains MHRA approval in the UK
